Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

← catalyst calendar

NCT05893537

Sponsored by Cognition Therapeutics (industry) · CGTX — their whole pipeline →.

Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
100actual
Sites
19
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

The trial was closed as part of a strategic business decision.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-06-16actualWhen the study began enrolling
Primary completion2025-03-04actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-03-28actualThe whole study's end, after follow-up
First posted2023-06-08actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-04-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Age-Related Macular Degeneration

Interventions

  • Drug: Active Comparator CT1812
  • Drug: Placebo Comparator

Primary outcome

what the primary-completion date above is the date OF
Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye.
measured Baseline through Week 104

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CGTX's whole pipeline · Catalyst calendar · Every registered study · What changed